From: Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics
Molecular process
Target
Drug combination with PARPi
Lipid metabolism
FASN
PARPi + TVB-2640
NF-κB signaling
IκBα
PARPi + Bortezomib
Cell proliferation
ElF5A-2
PARPi + N(1)-guanyl-1,7,-diamineohephane (GC7)
Mitotic exit
UBE2S/APC/C
PARPi + proTAME